Genome-scale integration of transcriptome and metabolome unveils squalene synthase and dihydrofolate reductase as targets against AML cells resistant to chemotherapy

Genome-scale integration of transcriptome and metabolome unveils squalene synthase and dihydrofolate reductase as targets against AML cells resistant to chemotherapy

The development of resistance to chemotherapeutic agents, such as Doxorubicin (DOX) and cytarabine (AraC), is one of the greatest challenges to the successful treatment of Acute Myeloid Leukemia (AML). Such acquisition is often underlined by a metabolic reprogramming that can provide a therapeutic o...

Full description

Bibliographic Details
Main Authors: Effrosyni Karakitsou, Carles Foguet, Miriam G. Contreras Mostazo, Nina Kurrle, Frank Schnütgen, Martin Michaelis, Jindrich Cinatl, Silvia Marin, Marta Cascante
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Computational and Structural Biotechnology Journal
Subjects:
Metabolic models
Drug resistance
Acute Myeloid Leukemia (AML)
Metabolic vulnerabilities
Drug targets
Online Access:http://www.sciencedirect.com/science/article/pii/S2001037021002877

Internet

http://www.sciencedirect.com/science/article/pii/S2001037021002877

Similar Items